The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS

Nancy A. Hessol, Sharon Pipkin, Sandra Schwarcz, Rosemary D Cress, Peter Bacchetti, Susan Scheer

Research output: Contribution to journalArticle

161 Citations (Scopus)

Abstract

Highly active antiretroviral therapy (HAART) has dramatically reduced the incidence of acquired immunodeficiency syndrome (AIDS) and increased AIDS survival time, but little is known about its impact on cancer. Data from adults in the San Francisco, California, AIDS surveillance registry were computer matched with the California Cancer Registry. Age-, sex-, and race-adjusted standardized incidence ratios (SIRs) were computed, and proportional hazards models evaluated the effect of HAART use on cancer incidence and cancer survival time. Among 14,210 adults with AIDS diagnosed in 1990-2000, 482 non-AIDS-defining cancers were diagnosed. Compared with rates for the general population, significantly increased cancer incidence rates were observed for anal (SIR = 13.4), Hodgkin's lymphoma (SIR = 11.5), liver (SIR = 3.6), oral cavity and pharynx (SIR = 2.6), respiratory (SIR = 2.6), leukemia (SIR = 2.4), skin melanoma (SIR = 2.4), and prostate (SIR = 1.7) cancers. Risk of liver cancer was lower with HAART use (relative hazard (RH) = 0.32). Risk of anal cancer increased after 1995 (RH = 2.9). Respiratory cancer (RH = 0.40) and Hodgkin's lymphoma (RH = 0.17) showed increased cancer survival time with HAART use, while anal cancer survival may have been slightly decreased (RH = 1.4). The impact of HAART on non-AIDS-defining cancer incidence rates and survival is not uniform, and the mechanism(s) responsible for these differences should be investigated further.

Original languageEnglish (US)
Pages (from-to)1143-1153
Number of pages11
JournalAmerican Journal of Epidemiology
Volume165
Issue number10
DOIs
StatePublished - May 2007
Externally publishedYes

Fingerprint

Highly Active Antiretroviral Therapy
Acquired Immunodeficiency Syndrome
Incidence
Neoplasms
Anus Neoplasms
Hodgkin Disease
Registries
San Francisco
Liver Neoplasms
Pharynx
Proportional Hazards Models
Mouth
Prostate
Melanoma
Leukemia
Survival Rate

Keywords

  • Acquired immunodeficiency syndrome
  • Antiretroviral therapy, highly active
  • HIV infections
  • Incidence
  • Neoplasms
  • Survival

ASJC Scopus subject areas

  • Epidemiology

Cite this

The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. / Hessol, Nancy A.; Pipkin, Sharon; Schwarcz, Sandra; Cress, Rosemary D; Bacchetti, Peter; Scheer, Susan.

In: American Journal of Epidemiology, Vol. 165, No. 10, 05.2007, p. 1143-1153.

Research output: Contribution to journalArticle

Hessol, Nancy A. ; Pipkin, Sharon ; Schwarcz, Sandra ; Cress, Rosemary D ; Bacchetti, Peter ; Scheer, Susan. / The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. In: American Journal of Epidemiology. 2007 ; Vol. 165, No. 10. pp. 1143-1153.
@article{fc2b355d7b154f48955b44f7bb23776f,
title = "The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS",
abstract = "Highly active antiretroviral therapy (HAART) has dramatically reduced the incidence of acquired immunodeficiency syndrome (AIDS) and increased AIDS survival time, but little is known about its impact on cancer. Data from adults in the San Francisco, California, AIDS surveillance registry were computer matched with the California Cancer Registry. Age-, sex-, and race-adjusted standardized incidence ratios (SIRs) were computed, and proportional hazards models evaluated the effect of HAART use on cancer incidence and cancer survival time. Among 14,210 adults with AIDS diagnosed in 1990-2000, 482 non-AIDS-defining cancers were diagnosed. Compared with rates for the general population, significantly increased cancer incidence rates were observed for anal (SIR = 13.4), Hodgkin's lymphoma (SIR = 11.5), liver (SIR = 3.6), oral cavity and pharynx (SIR = 2.6), respiratory (SIR = 2.6), leukemia (SIR = 2.4), skin melanoma (SIR = 2.4), and prostate (SIR = 1.7) cancers. Risk of liver cancer was lower with HAART use (relative hazard (RH) = 0.32). Risk of anal cancer increased after 1995 (RH = 2.9). Respiratory cancer (RH = 0.40) and Hodgkin's lymphoma (RH = 0.17) showed increased cancer survival time with HAART use, while anal cancer survival may have been slightly decreased (RH = 1.4). The impact of HAART on non-AIDS-defining cancer incidence rates and survival is not uniform, and the mechanism(s) responsible for these differences should be investigated further.",
keywords = "Acquired immunodeficiency syndrome, Antiretroviral therapy, highly active, HIV infections, Incidence, Neoplasms, Survival",
author = "Hessol, {Nancy A.} and Sharon Pipkin and Sandra Schwarcz and Cress, {Rosemary D} and Peter Bacchetti and Susan Scheer",
year = "2007",
month = "5",
doi = "10.1093/aje/kwm017",
language = "English (US)",
volume = "165",
pages = "1143--1153",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS

AU - Hessol, Nancy A.

AU - Pipkin, Sharon

AU - Schwarcz, Sandra

AU - Cress, Rosemary D

AU - Bacchetti, Peter

AU - Scheer, Susan

PY - 2007/5

Y1 - 2007/5

N2 - Highly active antiretroviral therapy (HAART) has dramatically reduced the incidence of acquired immunodeficiency syndrome (AIDS) and increased AIDS survival time, but little is known about its impact on cancer. Data from adults in the San Francisco, California, AIDS surveillance registry were computer matched with the California Cancer Registry. Age-, sex-, and race-adjusted standardized incidence ratios (SIRs) were computed, and proportional hazards models evaluated the effect of HAART use on cancer incidence and cancer survival time. Among 14,210 adults with AIDS diagnosed in 1990-2000, 482 non-AIDS-defining cancers were diagnosed. Compared with rates for the general population, significantly increased cancer incidence rates were observed for anal (SIR = 13.4), Hodgkin's lymphoma (SIR = 11.5), liver (SIR = 3.6), oral cavity and pharynx (SIR = 2.6), respiratory (SIR = 2.6), leukemia (SIR = 2.4), skin melanoma (SIR = 2.4), and prostate (SIR = 1.7) cancers. Risk of liver cancer was lower with HAART use (relative hazard (RH) = 0.32). Risk of anal cancer increased after 1995 (RH = 2.9). Respiratory cancer (RH = 0.40) and Hodgkin's lymphoma (RH = 0.17) showed increased cancer survival time with HAART use, while anal cancer survival may have been slightly decreased (RH = 1.4). The impact of HAART on non-AIDS-defining cancer incidence rates and survival is not uniform, and the mechanism(s) responsible for these differences should be investigated further.

AB - Highly active antiretroviral therapy (HAART) has dramatically reduced the incidence of acquired immunodeficiency syndrome (AIDS) and increased AIDS survival time, but little is known about its impact on cancer. Data from adults in the San Francisco, California, AIDS surveillance registry were computer matched with the California Cancer Registry. Age-, sex-, and race-adjusted standardized incidence ratios (SIRs) were computed, and proportional hazards models evaluated the effect of HAART use on cancer incidence and cancer survival time. Among 14,210 adults with AIDS diagnosed in 1990-2000, 482 non-AIDS-defining cancers were diagnosed. Compared with rates for the general population, significantly increased cancer incidence rates were observed for anal (SIR = 13.4), Hodgkin's lymphoma (SIR = 11.5), liver (SIR = 3.6), oral cavity and pharynx (SIR = 2.6), respiratory (SIR = 2.6), leukemia (SIR = 2.4), skin melanoma (SIR = 2.4), and prostate (SIR = 1.7) cancers. Risk of liver cancer was lower with HAART use (relative hazard (RH) = 0.32). Risk of anal cancer increased after 1995 (RH = 2.9). Respiratory cancer (RH = 0.40) and Hodgkin's lymphoma (RH = 0.17) showed increased cancer survival time with HAART use, while anal cancer survival may have been slightly decreased (RH = 1.4). The impact of HAART on non-AIDS-defining cancer incidence rates and survival is not uniform, and the mechanism(s) responsible for these differences should be investigated further.

KW - Acquired immunodeficiency syndrome

KW - Antiretroviral therapy, highly active

KW - HIV infections

KW - Incidence

KW - Neoplasms

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=34447114504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447114504&partnerID=8YFLogxK

U2 - 10.1093/aje/kwm017

DO - 10.1093/aje/kwm017

M3 - Article

C2 - 17344204

AN - SCOPUS:34447114504

VL - 165

SP - 1143

EP - 1153

JO - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 10

ER -